Products

IBG-NEVCELL CELL THERAPY PRODUCTS:

Mesenchymal Stem Cells (MSCs)

MSCs are resident stromal cells found in adult (adipose tissue, bone marrow, synovium) or perinatal tissues (umbilical cord). They exert their clinical efficacy by accelerating the healing process and reducing inflammation (Jimenez-Puerta et al., 2020). When applied systemically, MSCs home to the damaged tissue via molecules that trigger cell migration and engraft at the target site (Brown et al., 2019). Within the damaged tissue, they secrete factors that influence specific physiological mechanisms locally and systemically (Fu et al., 2019). Ultimately, MSCs contribute to the formation of a pro-regenerative microenvironment that promotes local tissue repair and regeneration (Hu et al., 2018).
In addition, MSCs have immunomodulatory effects. These effects are exerted through direct cell-to-cell contact or via the secretion of specific molecules (such as TGFβ, PGE2, IL-10). In this way, they inhibit the proliferation of immune cells and control the secretion of cytokines and chemokines (Jiang & Xu, 2020).
There are more than 10 MSC products approved by authorities worldwide. In Europe, Alofisel, which is approved by the European Medicines Agency (EMA), is an allogeneic MSC product derived from adipose tissue and is clinically effective for Crohn’s disease-related fistulas.
MSCs can be applied in the following indications:

• Osteoarthritis
• Bone and cartilage diseases
• Graft-versus-host disease (GVHD)
• Autoimmune diseases
• Spinal cord injuries
• Parkinson’s disease
• Multiple sclerosis
• Degenerative disc disease
• Alzheimer’s disease
• Myocardial infarction
• Retinal degenerative diseases
• Crohn’s disease (Crohn’s fistulas)
• Type 1 diabetes
• Bone deficiency and neurological disorders

 Fibroblasts

Fibroblasts are the primary cells of connective tissue and are responsible for maintaining and regenerating the integrity of connective tissue and skin. Located in the dermis (the middle layer of the skin), these cells synthesize extracellular matrix proteins such as collagen and elastin, which give the skin its firmness, elasticity, and youthful appearance, as well as glycoproteins like hyaluronic acid. Clinical trials have shown that fibroblasts do not cause serious adverse effects such as hypersensitivity reactions, which are commonly associated with other dermal fillers (e.g., FDA-approved Azficel-T). Thanks to these properties, autologous fibroblasts are an attractive cellular therapy product for various dermatological indications.

Chondrocyte / Chondromembrane

Chondromembrane is a product formed by seeding cultured chondroblast cells, isolated from cartilage tissue, onto three-dimensional matrices. These cultured autologous chondrocytes are implanted into the debrided defect area using the scaffold structures. This technique potentially reduces surgical time and allows for arthroscopic implantation, resulting in hyaline-like cartilage regeneration.

It is used in the treatment of the following conditions:

• Knee joint cartilage lesions
• Cartilage tissue damage and injuries
• Joint degeneration
• Patellar lesions
• Tendon injuries, tendinitis problems
• Sports injuries
• Femoral condyle injuries
• Grade III and IV cartilage lesions
• Osteoarthritis

Stromal Vascular Fraction (SVF)

SVF is a cell cocktail obtained by isolating regenerative cells from fresh liposuction material (lipoaspirate). It contains fibroblastic cells, endothelial cells, macrophages, smooth muscle cells, and stem cells.
The regenerative cells within SVF have characteristics such as differentiation capacity, wound healing ability, paracrine signaling, prevention of cell death, and immune system modulation.
In plastic surgery, SVF is mainly used in combination with fat grafts after lipodystrophy correction and breast reconstruction to enhance graft viability. Beyond these applications, it also has potential uses in the repair of joint cartilage defects, treatment of rheumatoid arthritis, osteoarthritis, tissue engineering applications, and various regenerative medicine purposes.

References

1.  Jimenez-Puerta, Gonzalo José, Juan Antonio Marchal, Elena López-Ruiz, and Patricia Gálvez-Martín. 2020. “Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use.” Journal of Clinical Medicine 9 (2). https://doi.org/10.3390/JCM9020445.
2. Brown, Christina, Christina McKee, Shreeya Bakshi, Keegan Walker, Eryk Hakman, Sophia Halassy, David Svinarich, Robert Dodds, Chhabi K. Govind, and G. Rasul Chaudhry. 2019. “Mesenchymal Stem Cells: Cell Therapy and Regeneration Potential.” Journal of Tissue Engineering and Regenerative Medicine 13 (9): 1738–55. https://doi.org/10.1002/TERM.2914.
3. Fu, Xiaorong, Ge Liu, Alexander Halim, Yang Ju, Qing Luo, and Guanbin Song. 2019. “Mesenchymal Stem Cell Migration and Tissue Repair.” Cells 2019, Vol. 8, Page 784 8 (8): 784. https://doi.org/10.3390/CELLS8080784.
4. Hu, Michael S., Mimi R. Borrelli, H. Peter Lorenz, Michael T. Longaker, and Derrick C. Wan. 2018. “Mesenchymal Stromal Cells and Cutaneous Wound Healing: A Comprehensive Review of the Background, Role, and Therapeutic Potential.” Stem Cells International 2018. https://doi.org/10.1155/2018/6901983.
5. Jiang, Wei, and Jianyong Xu. 2020. “Immune Modulation by Mesenchymal Stem Cells.” Cell Proliferation 53 (1). https://doi.org/10.1111/CPR.12712